Lunit has announced a collaboration with Daiichi Sankyo to advance AI-driven biomarker discovery and translational oncology research. This partnership aims to leverage Lunit's AI expertise with Daiichi Sankyo's oncology pipeline to accelerate the development of novel cancer therapies.
This strategic partnership combines Lunit's advanced AI capabilities in image analysis and biomarker identification with Daiichi Sankyo's extensive oncology drug development expertise. It has the potential to significantly accelerate the discovery and validation of novel biomarkers, leading to more precise and effective cancer treatments. This collaboration could also set a precedent for AI integration in pharmaceutical R&D pipelines.
Lunit partners with Daiichi Sankyo.
Collaboration focuses on AI-driven biomarker discovery.
Aims to accelerate translational oncology research and therapy development.
This collaboration involves a global pharmaceutical company and a leading AI company, with the aim of advancing oncology research and drug development, impacting patient care and treatment strategies worldwide.
Collaboration focuses on AI-driven biomarker discovery.
Aims to accelerate translational oncology research and therapy development.
Sign in to save notes on signals.
Sign In